Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C

Abstract

Potential liver toxicity is an important consideration for antiretroviral selection among patients coinfected with HIV and viral hepatitis (B and/or C). We sought to describe the hepatic safety profile of raltegravir in this population